Watch PVLA. Know when insiders buy.
One email the day a filing lands. Free.
PVLA
PALVELLA THERAPEUTICS, INC.
123.92
+0.96 +0.78%
USD · Oct 20, 07:41 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
30
FLAG · insiders 25, shorts 35
Insiders, 90 days
−$9.1M
net selling · 0 buys, 35 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$61.7MNET CASH —52W 70.43 – 158.13NEXT EARNINGS Nov 11 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$21.4M | −$21.9M | — | -1.52 | −$12.8M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$14.9M | −$15.8M | — | -1.20 | −$10.9M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | — | — | — | −$11.3M | −$12.7M | — | -1.08 | −$4.9M | — | — | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$10.2M | −$11.3M | — | -1.03 | −$7.9M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$9.3M | −$9.5M | — | -0.86 | −$5.4M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$7.9M | −$8.2M | — | -0.74 | −$6.8M | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.4M | −$4M | −110.2% | 0.12 | −$5.4M | — | — | Mar 31 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$5.1M | −$6.8M | — | -3.94 | −$2.7M | $0 | −$2.7M | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$2.9M | −$4.2M | — | -2.47 | −$1.6M | $0 | −$1.6M | Nov 12 |
| Q1 2024 · Mar 31 | $53K | — | — | −$1.8M | −$2.5M | — | -1.54 | −$1.1M | $0 | −$1.1M | Nov 12 |
| Q4 2023 · Dec 31derived | $1.3M | — | — | $13.4M | $38.6M | — | 20.50 | $20.4M | −$13K | $20.5M | Mar 31 |
| Q3 2023 · Sep 30 | $19.5M | — | — | −$11.8M | −$10.8M | — | -8.70 | −$9.7M | $69K | −$9.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$38.6M | −$41.7M | — | -3.71 | −$25M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$14.1M | −$17.4M | — | -7.83 | −$10.8M | — | — | — | — |
| FY2023 · to Dec 31 | $42.8M | — | −$11.9M | $18.7M | 43.7% | 2.17 | −$13.7M | $171K | −$13.9M | — | — |
| FY2022 · to Dec 31 | $25.9M | — | −$43.5M | −$33.3M | -128.5% | -0.45 | −$59.9M | $1M | −$61M | — | — |
| FY2021 · to Dec 31 | $31.4M | — | −$51.8M | −$45.7M | -145.6% | -0.71 | −$7.7M | $949K | −$8.6M | — | — |
| FY2020 · to Dec 31 | $29.3M | — | −$33.9M | −$37.2M | -127.0% | -0.68 | −$45.9M | $2.7M | −$48.6M | — | — |
Every number comes from PALVELLA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.